ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO832

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Treatment of Post Kidney Transplant Anemia

Session Information

Category: Transplantation

  • 2002 Transplantation: Clinical

Authors

  • Ogata, Masatomo, St. Marianna University School of Medicine, Kawasaki, Japan
  • Miyauchi, Takamasa, St. Marianna University School of Medicine, Kawasaki, Japan
  • Murata, Marie, St. Marianna University School of Medicine, Kawasaki, Japan
  • Terashita, Maho, St. Marianna University School of Medicine, Kawasaki, Japan
  • Osako, Kiyomi, St. Marianna University School of Medicine, Kawasaki, Japan
  • Shinoda, Kazunobu, St. Marianna University School of Medicine, Kawasaki, Japan
  • Shibagaki, Yugo, St. Marianna University School of Medicine, Kawasaki, Japan
  • Yazawa, Masahiko, St. Marianna University School of Medicine, Kawasaki, Japan
Background

We previously reported the short-term efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHi) for the treatment of post kidney transplant anemia (PTA). The present report re-analyzes our experience with HIF-PHi for PTA in the context of longer follow-ups and using a different class of HIF-PHi.

Methods

Nine kidney transplant recipients (KTRs) in our institute who were administered HIF-PHi for PTA were evaluated. The indication of HIF-PHi to erythropoiesis-stimulating agent (ESA) naive patients was an hemoglobin (Hb) level below 11.0 g/dL, and to ESA treated patients was an Hb level below 13.0 g/dL. Either roxadustat (Rox) or enarodustat (Ena) was employed as per the recommended dose adjustments to achieve target Hb levels between 11.0-13.0 g/dL. Anemia-related parameters, including Hb, total iron - binding capacity, and ferritin levels were evaluated along with LDL cholesterol up to 14 months. Adverse events of HIF-PHi were defined as thromboembolic events and malignancy.

Results

Rox and Ena were prescribed to 6 and 3 KTRs, respectively. The mean eGFR was 25.6 mL/min/1.73 m2. Hb levels and iron metabolism are shown in Figure (Solid line: Ena and dashed line: Rox). While most of the KTRs demonstrated an increase or maintain in their Hb levels from baseline, 2 of them kept their Hb level below the target ranges. Further, a few of the Rox-treated KTRs showed rapidly increase and decrease in their Hb and ferritin levels, respectively, despite being prescribed the recommended initial dose. Additionally, a drop in LDL cholesterol levels was only observed in the Rox-treated group. Adverse events were not recorded during the observation period.

Conclusion

Based on the recommended dose of HIF-PHi, treatment with Rox resulted in a more rapid increase in Hb levels along with a stronger improvement in iron utilization as compared to that seen in treatment with Ena. For PTA, HIF-PHi would be safe and useful in clinical use.